Clinical Trials Epilepsy Media Topical 
The Cannigma
MAY 19, 2021
This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.
MMJ Recs
DECEMBER 22, 2023
Medical marijuana, once a controversial and stigmatized topic, has undergone a remarkable transformation in the eyes of the American public. Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 20, 2021
(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., Media: Laura Radocaj. For more information, please visit www.virpaxpharma.com. About Altasciences.
Project CBD
FEBRUARY 28, 2023
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. Epilepsy Behav.
Cannabis Law Report
DECEMBER 8, 2021
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
Cannabis Law Report
DECEMBER 28, 2021
We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Epoladerm™ Epoladerm is a diclofenac topical spray film product candidate that is being developed for pain associated with osteoarthritis of the knee. to conduct this study in Canada.
Cannabis Law Report
NOVEMBER 10, 2021
Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (a rare pediatric disease) and adults.
Expert insights. Personalized for you.
137 
Let's personalize your content